?
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
News
News
Material Information- Clarification of Media Report
2026-05-11
Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers
2026-05-07
Material Information- Announcement of the Board’s Resolution to redeem and cancel restricted employee shares for a capital reduction
2026-05-07
Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q1.
2026-05-07
Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q1 Financial Report on May 7, 2026
2026-04-29
Material Information- Announces on behalf of the subsidiary Handa Oncology, LLC, regarding the 505(b)(2) new formulation drug HND-039 citizen petition to the FDA examination
2026-04-19
Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares
2026-04-16
Material Information- Announcement of the Completion of the Company’s Treasury Share Buyback
2026-03-31
Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities
2026-03-18
Material Information- Correction to the Material Information announced on March 12, 2026: Announcement of the newly appointed Chief Innovation Officer
2026-03-16
1
2
›
